Compare ASTC & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTC | JAGX |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.0M |
| IPO Year | 2020 | 2014 |
| Metric | ASTC | JAGX |
|---|---|---|
| Price | $2.31 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 56.8K | ★ 229.7K |
| Earning Date | 05-12-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | 82.42 |
| EPS | ★ 0.25 | N/A |
| Revenue | $1,000,000.00 | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $0.22 |
| 52 Week High | $8.01 | $8.00 |
| Indicator | ASTC | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 32.59 | 52.08 |
| Support Level | $2.25 | $1.74 |
| Resistance Level | $2.45 | $4.13 |
| Average True Range (ATR) | 0.16 | 0.55 |
| MACD | -0.05 | -0.11 |
| Stochastic Oscillator | 6.80 | 23.44 |
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.